Anti-HECTD1 抗体 (ab101992)
Key features and details
- Rabbit polyclonal to HECTD1
- Suitable for: WB, IP
- Reacts with: Human
- Isotype: IgG
製品の概要
-
製品名
Anti-HECTD1 antibody -
製品の詳細
Rabbit polyclonal to HECTD1 -
由来種
Rabbit -
アプリケーション
適用あり: WB, IPmore details -
種交差性
交差種: Human
交差が予測される動物種: Mouse, Rat, Rabbit, Horse, Chicken, Guinea pig, Cow, Dog, Turkey, Pig, Chimpanzee, Zebrafish, Rhesus monkey, Gorilla, Orangutan, Xenopus tropicalis -
免疫原
Synthetic peptide, corresponding to N terminal amino acids 1-50 of Human HECTD1 (AAP13073.1).
-
特記事項
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
バッファー
pH: 7
Preservative: 0.09% Sodium azide
Constituent: Tris citrate/phosphate -
Concentration information loading...
-
精製度
Immunogen affinity purified -
ポリ/モノ
ポリクローナル -
アイソタイプ
IgG -
研究分野
関連製品
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
-
Recombinant Protein
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab101992の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
WB |
1/2000 - 1/10000. Predicted molecular weight: 290 kDa.
|
|
IP |
Use at 2-5 µg/mg of lysate.
|
特記事項 |
---|
WB
1/2000 - 1/10000. Predicted molecular weight: 290 kDa. |
IP
Use at 2-5 µg/mg of lysate. |
ターゲット情報
-
機能
Probable E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. May be required for development of the head mesenchyme and neural tube closure. -
パスウェイ
Protein modification; protein ubiquitination. -
配列類似性
Belongs to the UPL family. K-HECT subfamily.
Contains 4 ANK repeats.
Contains 1 HECT (E6AP-type E3 ubiquitin-protein ligase) domain.
Contains 1 MIB/HERC2 domain. - Information by UniProt
-
参照データベース
- Entrez Gene: 25831 Human
- Entrez Gene: 207304 Mouse
- Entrez Gene: 362736 Rat
- SwissProt: Q9ULT8 Human
- SwissProt: Q69ZR2 Mouse
- Unigene: 708017 Human
- Unigene: 249391 Mouse
-
別名
- E3 ligase for inhibin receptor antibody
- E3 ubiquitin protein ligase HECTD1 antibody
- E3 ubiquitin-protein ligase HECTD1 antibody
see all
画像
-
All lanes : Anti-HECTD1 antibody (ab101992) at 0.1 µg/ml
Lane 1 : HeLa whole cell lysate at 50 µg
Lane 2 : HeLa whole cell lysate at 15 µg
Lane 3 : HeLa whole cell lysate at 5 µg
Lane 4 : 293T whole cell lysate at 50 µg
Developed using the ECL technique.
Predicted band size: 290 kDa
Exposure time: 3 minutes -
ab101992 at 1 µg/ml staining HECTD1 in HeLa cell lysate immunoprecipitated using ab101992 at 3 µg/mg lysate (1 mg/IP; 20% of IP loaded/lane). Detection: Chemiluminescence with exposure time of 3 minutes
プロトコール
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (6)
ab101992 は 6 報の論文で使用されています。
- Meng M & Wu YC LMX1B Activated Circular RNA GFRA1 Modulates the Tumorigenic Properties and Immune Escape of Prostate Cancer. J Immunol Res 2022:7375879 (2022). PubMed: 35832649
- Harris LD et al. The deubiquitinase TRABID stabilizes the K29/K48-specific E3 ubiquitin ligase HECTD1. J Biol Chem 296:100246 (2021). PubMed: 33853758
- Saez I et al. Insights into the ubiquitin-proteasome system of human embryonic stem cells. Sci Rep 8:4092 (2018). PubMed: 29511261
- Flack JE et al. Wnt-Dependent Inactivation of the Groucho/TLE Co-repressor by the HECT E3 Ubiquitin Ligase Hyd/UBR5. Mol Cell 67:181-193.e5 (2017). PubMed: 28689657
- Byrne R et al. Activity-Based Probes for HECT E3 Ubiquitin Ligases. Chembiochem 18:1415-1427 (2017). PubMed: 28425671
- Loganzo F et al. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments. Mol Cancer Ther 14:952-63 (2015). PubMed: 25646013